NZ629459A - Methods for treating cancer using tor kinase inhibitor combination therapy - Google Patents
Methods for treating cancer using tor kinase inhibitor combination therapyInfo
- Publication number
- NZ629459A NZ629459A NZ629459A NZ62945914A NZ629459A NZ 629459 A NZ629459 A NZ 629459A NZ 629459 A NZ629459 A NZ 629459A NZ 62945914 A NZ62945914 A NZ 62945914A NZ 629459 A NZ629459 A NZ 629459A
- Authority
- NZ
- New Zealand
- Prior art keywords
- kinase inhibitor
- tor kinase
- methods
- combination therapy
- treating cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 229940043355 kinase inhibitor Drugs 0.000 title abstract 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 title abstract 3
- 238000002648 combination therapy Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 abstract 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 abstract 2
- UFKLYTOEMRFKAD-UHFFFAOYSA-N 3-[6-(2-hydroxypropan-2-yl)pyridin-3-yl]-5-(4-methoxycyclohexyl)-7,8-dihydropyrazino[2,3-b]pyrazin-6-one Chemical group C1CC(OC)CCC1N1C2=NC(C=3C=NC(=CC=3)C(C)(C)O)=CN=C2NCC1=O UFKLYTOEMRFKAD-UHFFFAOYSA-N 0.000 abstract 1
- -1 5-Substituted Quinazolinone Compound Chemical class 0.000 abstract 1
- GMYLVKUGJMYTFB-UHFFFAOYSA-N 5-ethyl-3-[2-methyl-6-(1h-1,2,4-triazol-5-yl)pyridin-3-yl]-7,8-dihydropyrazino[2,3-b]pyrazin-6-one Chemical compound N1=C2N(CC)C(=O)CNC2=NC=C1C(C(=N1)C)=CC=C1C1=NN=CN1 GMYLVKUGJMYTFB-UHFFFAOYSA-N 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 201000007270 liver cancer Diseases 0.000 abstract 1
- 208000014018 liver neoplasm Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 201000000050 myeloid neoplasm Diseases 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Disclosed herein is the use of an effective amount of an effective amount of a TOR kinase inhibitor represented by structural formula (I) and an effective amount of a 5-Substituted Quinazolinone Compound in the manufacture of a medicament for treating or preventing cancer, particularly a liver cancer or a blood borne cancer which includes a lymphoma, a leukemia or a mutliple myeloma, wherein the variables shown in formula (I) are as defined in the specification. The preferred TOR kinase inhibitor is 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-(trans-4-methoxycyclohexyl)-3,4-dihydropyrazino-[2,3-b]pyrazin-2(1H)-one or 1-ethyl-7-(2-methyl-6-(4H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361813089P | 2013-04-17 | 2013-04-17 | |
| US201361908498P | 2013-11-25 | 2013-11-25 | |
| PCT/US2014/034321 WO2014172436A1 (en) | 2013-04-17 | 2014-04-16 | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ629459A true NZ629459A (en) | 2017-07-28 |
Family
ID=59713711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ629459A NZ629459A (en) | 2013-04-17 | 2014-04-16 | Methods for treating cancer using tor kinase inhibitor combination therapy |
Country Status (1)
| Country | Link |
|---|---|
| NZ (1) | NZ629459A (en) |
-
2014
- 2014-04-16 NZ NZ629459A patent/NZ629459A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018500792A1 (en) | Benzolactam compounds as protein kinase inhibitors | |
| NZ628421A (en) | Treatment of cancer with tor kinase inhibitors | |
| NZ628407A (en) | Treatment of cancer with tor kinase inhibitors | |
| NZ628420A (en) | Treatment of cancer with tor kinase inhibitors | |
| RS61319B1 (en) | Pyrazolo[1,5-a]pyrimidines useful as inhibitors of atr kinase for the treatment of cancer diseases | |
| NZ628416A (en) | Treatment of cancer with tor kinase inhibitors | |
| MX370814B (en) | Substituted pyrazolo[3,4-d]pyrimidines and uses thereof. | |
| MA37316B1 (en) | Pyrido [2,3-d] pyrimidine-substituted 2-amino, 6-phenyl derivatives as inhibitors of raf kinase | |
| UA110697C2 (en) | The use of inhibitors tor-kinase for the treatment of tumors in patients with reduced protein pampk and / or activity ampk | |
| NZ751509A (en) | Combination therapy with 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one | |
| MX347917B (en) | Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof. | |
| MX2014010589A (en) | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE. | |
| NZ630489A (en) | Bicyclic pyrazinone derivatives | |
| MX2018003861A (en) | New pyrrolo[2,3-d]pyrimidine derivatives as dual dyrk1/clk1 inhibitors. | |
| GEP20156333B (en) | (1,2,4)triazolo[4,3-a]quinoxaline derivatives as inhibitors of phosphodiesterases | |
| NZ629230A (en) | Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one | |
| MY169029A (en) | Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof | |
| MX2014008864A (en) | Triazolo[4,5-d]pyrimidine derivatives. | |
| NZ630580A (en) | 6-(4-(1-amino-3-hydroxycyclobutyl)phenyl)-5-phenyl(furo,thieno or pyrrolo) [2, 3-d] pyrimidin-4-one derivatives for the treatment of cancer | |
| NZ702939A (en) | Process for making amino acid compounds | |
| NZ714742A (en) | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use | |
| NZ629459A (en) | Methods for treating cancer using tor kinase inhibitor combination therapy | |
| MX2015015880A (en) | PHARMACEUTICAL COMPOSITIONS OF 7-(6-(2-HYDROXYPROPAN-2-YL)PYRIDIN -3-YL)-1-((TRANS)-4-METHOXYCYCLOHEXYL)-3,4-DIHYDROPYRAZINO[2,3-< i>B]PYRAZIN-2(1H)-ONE, A SOLID FORM THEREOF AND METHODS OF THEIR USE. | |
| WO2014153464A3 (en) | 2-substituted imidazo[4,5-d]phenanthroline derivatives and their use in the treatment of cancer | |
| PH12015500060A1 (en) | Anti-tumoral composition comprising the compound 1-(6-{[6-(4-fluorophenyl) compound 1-(6-{[6-(4-fluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}-1,3-benz |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 APR 2019 BY COMPUTER PACKAGES INC Effective date: 20180331 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 APR 2020 BY COMPUTER PACKAGES INC Effective date: 20190402 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 APR 2021 BY COMPUTER PACKAGES INC Effective date: 20200331 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 APR 2022 BY CPA GLOBAL Effective date: 20210305 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 APR 2023 BY CPA GLOBAL Effective date: 20220304 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 APR 2024 BY CPA GLOBAL Effective date: 20230303 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 APR 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20240301 |